Veterinary Reference Laboratory (VRL) Market Size, Share & Trends Analysis Report By Product (Clinical Chemistry, Hematology, Immunodiagnostics, Molecular Diagnostics, Others), By Applications (Clinical Pathology, Toxicology, Productivity Testing, Others), By End Use, By Region, and Segment Forecasts - 2035

Opportunity

""Molecular testing and virtual diagnostic networks are creating new service opportunities.""

Molecular Diagnostics provides one of the strongest expansion opportunities because PCR-based testing can identify pathogens with high analytical specificity and support earlier disease management. The segment is estimated to represent approximately 19% of current market demand but is positioned to expand faster than conventional laboratory categories. Commercial veterinary laboratories already provide PCR and ELISA services for cattle, pigs, sheep, and goats, with many tests offering results within approximately 24 hours. Molecular panels can simultaneously address several pathogens associated with similar clinical symptoms, improving diagnostic efficiency. Companion animal applications are also broadening as veterinarians use molecular methods for infectious diseases, gastrointestinal conditions, respiratory infections, and vector-borne diseases. As sequencing costs decline and laboratory automation improves, veterinary reference laboratories can progressively expand from single-target assays toward larger multiplex panels and more sophisticated genomic analysis.

Virtual reference laboratories create a second major opportunity by extending specialist expertise beyond the physical laboratory. A veterinary practice may have access to several in-clinic diagnostic instruments but lack an on-site pathologist, radiologist, cardiologist, neurologist, or dentist. Cloud platforms can connect clinical data and images to specialists located hundreds or thousands of kilometers away. In July 2026, a major animal health company announced an agreement to acquire a teleradiology platform providing around-the-clock specialist access and AI-assisted reporting. The model integrates teleradiology, mobile ultrasound, outpatient imaging, and cloud image storage into a broader diagnostic ecosystem. Virtual laboratories can therefore complement physical reference laboratories rather than replace them, potentially giving smaller practices access to specialist-level interpretation 24 hours per day while central laboratories continue processing complex biological specimens.

Challenge

""Maintaining diagnostic consistency across species, specimens, and testing platforms remains complex.""

Veterinary reference laboratories face greater biological diversity than many human diagnostic laboratories because testing spans numerous species with different physiological reference intervals, disease patterns, sample characteristics, and clinical requirements. A chemistry result considered normal in a dog may require different interpretation in a horse, cattle, sheep, goat, or cat. Laboratories must therefore maintain species-specific reference intervals and validated methodologies across potentially dozens of analytes. Hematology adds further complexity because cell morphology and instrument performance can differ between species. Molecular Diagnostics requires equally careful validation because pathogen prevalence and sample types vary across populations. Laboratories accredited to ISO 17025 for many PCR and ELISA procedures must maintain documentation, calibration, proficiency testing, and quality-control processes to ensure reliable performance.

Specimen logistics represents another persistent challenge. A centralized laboratory can receive thousands of tubes, swabs, tissue specimens, fecal samples, slides, and other materials each day, and many require temperature-controlled transportation or rapid processing. Pre-analytical errors occurring before the sample reaches the analyzer can materially affect results. Hemolysis, incorrect containers, insufficient sample volume, labeling errors, delayed transport, or inappropriate storage can make specimens unsuitable for analysis. New laboratories are therefore being positioned close to major transportation hubs; one 32,000-square-foot U.S. facility opened in 2025 directly adjacent to a large integrated air-logistics operation. Real-time specimen tracking and reduced handling can improve turnaround, but laboratories still depend on coordinated collection and transportation networks covering hundreds of veterinary clinics.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Veterinary Reference Laboratory (VRL) Market is segmented by product type into Clinical Chemistry, Hematology, Immunodiagnostics, Molecular Diagnostics, and Others, while applications comprise Clinical Pathology, Toxicology, Productivity Testing, and Others. Clinical Chemistry is estimated to hold approximately 31% market share, followed by Hematology at 22%, Immunodiagnostics at 20%, Molecular Diagnostics at 19%, and Others at 8%. Application demand is led by Clinical Pathology with approximately 61%, followed by Toxicology at 15%, Productivity Testing at 13%, and Others at 11%. The structure demonstrates the continuing importance of routine pathology while highlighting increasing demand for molecular and specialized testing.

By Types

Clinical Chemistry: Clinical Chemistry accounts for approximately 31% market share and remains the leading supplied diagnostic type because chemistry profiles are routinely used across wellness examinations, disease diagnosis, pre-anesthetic evaluation, emergency medicine, and chronic condition monitoring. Laboratories can measure more than 20 biochemical parameters across comprehensive panels, including enzymes, proteins, electrolytes, glucose, kidney-related markers, and metabolic indicators. Centralized laboratories offer broad menus and specialist review, while veterinary practices increasingly use point-of-care chemistry for urgent cases. Reference laboratories retain an advantage for advanced assays, quality assurance, confirmatory testing, and high-volume processing. Integration of newer biomarkers into commonly ordered chemistry profiles during 2026 demonstrates how routine panels continue to become more diagnostically informative.

Hematology: Hematology represents approximately 22% market share and is fundamental to evaluation of anemia, inflammation, infection, immune responses, platelet abnormalities, and systemic disease. Complete blood count testing can analyze more than 20 parameters, and technology is rapidly advancing at both reference laboratories and veterinary clinics. A cartridge-based AI-powered analyzer expanded to 24 parameters in April 2026, including cellular hemoglobin concentration mean and plateletcrit. Reference laboratories remain important when automated results require blood-film review, unusual cells are detected, or specialist interpretation is needed. Digital morphology and AI are likely to increase collaboration between clinic-based analyzers and centralized laboratory specialists rather than creating a purely competitive relationship.

Immunodiagnostics: Immunodiagnostics accounts for approximately 20% market share and supports infectious disease testing, endocrine evaluation, immune-related conditions, and antibody or antigen detection. ELISA remains an important platform in production animal diagnostics, with accredited laboratories providing assays for cattle, pigs, sheep, and goats. Immunodiagnostic methods are attractive because multiple samples can be processed efficiently in microplate formats, allowing laboratories to test dozens or hundreds of specimens per batch. The segment also complements Molecular Diagnostics because antibody and antigen detection can answer different clinical questions than pathogen nucleic acid detection. Laboratories increasingly combine the 2 approaches in surveillance programs to improve diagnostic coverage.

Molecular Diagnostics: Molecular Diagnostics represents approximately 19% market share and is expected to be one of the fastest-expanding diagnostic categories through 2035. Real-time PCR is widely used for veterinary infectious disease testing because it can identify pathogen-specific genetic material from blood, swabs, feces, tissues, and other specimens. Commercial laboratories offer PCR panels covering multiple pathogens, including 3-target enteric coronavirus testing for pigs. Molecular platforms are increasingly automated, enabling laboratories to process larger batches while maintaining traceability. Expansion of companion animal infectious disease panels and livestock surveillance is expected to support continued adoption, particularly as veterinarians require results within approximately 24 hours for clinically or economically significant infections.

Others: Others account for approximately 8% market share and encompass specialized testing that falls outside the 4 primary supplied diagnostic categories. These services can involve microbiology, histology, cytology, pathology, parasitology, and other advanced laboratory procedures. A new 32,000-square-foot U.S. reference laboratory opened in 2025 supports multiple diagnostic disciplines within one centralized facility, illustrating the importance of broad test menus. Specialized services are particularly valuable for cases requiring board-certified interpretation or techniques that individual clinics cannot justify operating internally. Digital transmission of images is also shortening the distance between laboratory specialists and veterinary practices.

By Applications

Clinical Pathology: Clinical Pathology dominates with approximately 61% market share because it combines many of the most frequently requested veterinary diagnostic services. Chemistry, hematology, cytology, immunodiagnostics, urinalysis, microbiology, histology, and molecular testing can all contribute to clinical case management. A single sick animal may require 3 or more diagnostic categories before a definitive diagnosis is established. Centralized laboratories provide scale by processing specimens from hundreds of veterinary clinics while maintaining specialized analyzers and professional interpretation. Growing chronic disease management in companion animals and increased preventive testing are strengthening the frequency of laboratory utilization beyond acute illness.

Toxicology: Toxicology represents approximately 15% market share and supports investigation of suspected poisoning, drug exposure, feed contamination, environmental toxins, medication monitoring, and forensic veterinary cases. Testing can involve blood, urine, tissues, stomach contents, feed, or environmental specimens, depending on the suspected substance. Specialized laboratories may use HPLC, LCMS, immunoassays, and other analytical platforms capable of detecting numerous compound classes. Toxicology is particularly important when clinical symptoms are nonspecific and laboratory confirmation influences treatment or legal investigation. Access to specialist equipment allows reference laboratories to provide testing that would be impractical for most individual veterinary practices.

Productivity Testing: Productivity Testing accounts for approximately 13% market share and is primarily associated with production animals where laboratory information supports herd health, breeding, pregnancy management, disease prevention, and production efficiency. Diagnostic providers offer pregnancy testing and infectious disease surveillance for cattle and other livestock, with certain services returning results within approximately 24 hours. Even a 1% improvement in reproductive or herd-health performance can have meaningful economic implications across large livestock operations. Laboratory testing therefore functions as both a healthcare tool and a production-management resource.

Others: Others represent approximately 11% market share and include veterinary laboratory applications not captured within Clinical Pathology, Toxicology, or Productivity Testing. Demand can involve surveillance programs, research testing, regulatory disease monitoring, pre-export certification, epidemiological investigations, and specialized animal health projects. Some programs require hundreds or thousands of specimens to be processed during disease investigations, creating demand for scalable laboratory capacity. Molecular and immunodiagnostic platforms are especially useful when large animal populations must be screened within limited timeframes.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 43% of the Veterinary Reference Laboratory (VRL) Market and remains the leading region because of its mature veterinary infrastructure, substantial companion animal population, livestock industry, and widespread diagnostic adoption. The United States supports extensive networks of veterinary clinics, specialty hospitals, reference laboratories, university diagnostic centers, and animal health companies. Recent national pet research collected responses from 7,519 participants in 2025 after surveying 7,539 in 2024 and 6,979 in 2023, reflecting continuing analysis of veterinary care utilization and pet ownership patterns. Increasing preventive care and chronic disease management are supporting routine chemistry and hematology testing.

Diagnostic infrastructure continues to expand. A 32,000-square-foot laboratory opened in Louisville during May 2025 as the largest reference laboratory within its operator's U.S. network, offering chemistry, hematology, cytology, microbiology, histology, and additional services. Its location beside a major air-logistics hub enables rapid specimen transportation from veterinary practices across the country. The region is also at the forefront of AI-enabled veterinary diagnostics. During 2026, a hematology platform expanded to 24 parameters, while a planned teleradiology acquisition sought to add 24/7 specialist access to a broader virtual reference laboratory model.

Europe

Europe represents approximately 27% of market demand and has well-developed veterinary diagnostic infrastructure across the United Kingdom, Germany, France, the Netherlands, Italy, Spain, Scandinavia, and other markets. Companion animal healthcare is sophisticated, while the region's large cattle, pig, poultry, and dairy sectors generate substantial surveillance requirements. Laboratories increasingly use PCR, ELISA, Clinical Chemistry, and Hematology across both companion and production animals. Regulatory disease-monitoring programs also generate recurring specimen volumes, making reference laboratories important components of national animal health infrastructure.

Consolidation is strengthening the region's commercial laboratory networks. In November 2025, a multinational animal health company acquired Veterinary Pathology Group, which operates multiple diagnostic laboratory locations across the United Kingdom and Ireland. The acquisition expanded pathology and multi-specialty testing capabilities while connecting regional laboratories with a broader diagnostics portfolio. European demand is also supported by high laboratory quality standards, including ISO 17025 accreditation for relevant testing procedures. Molecular Diagnostics is positioned to gain share from its current approximately 19% global level as surveillance increasingly depends on rapid pathogen-specific detection.

Asia-Pacific

Asia-Pacific accounts for approximately 23% market share and is projected to record the fastest regional growth at around 6.8% annually. China, India, Japan, South Korea, Australia, and Southeast Asia are expanding companion animal healthcare while maintaining some of the world's largest livestock populations. This creates dual demand for pet diagnostics and production-animal disease surveillance. Rising veterinary clinic sophistication is increasing the use of chemistry, hematology, immunodiagnostic, and molecular tests, while livestock producers require faster identification of economically significant diseases. The region's population exceeds 4 billion people, and increasing urbanization is contributing to growth in companion animal ownership across major cities.

Australia and New Zealand have mature veterinary diagnostic systems, including established commercial laboratories, while China and India offer substantial long-term expansion potential. Laboratory networks are increasingly investing in PCR and ELISA technologies because these platforms can process high specimen volumes and support infectious disease surveillance. Asia-Pacific's challenge is uneven diagnostic infrastructure between metropolitan and rural markets. Digital pathology and virtual consultation could help address this gap because specimens or images can be interpreted by specialists located hundreds of kilometers from the veterinary practice.

Middle East & Africa

Middle East & Africa represents approximately 4% of global market demand but has significant long-term requirements for livestock diagnostics. Africa's population exceeds 1.5 billion people, and animal agriculture remains economically important across many countries. Cattle, sheep, goats, poultry, and camels require disease surveillance to protect food supply, animal productivity, and cross-border trade. Veterinary reference laboratories are particularly important for infectious disease testing because outbreaks can affect thousands of animals and create substantial economic losses. Molecular and immunodiagnostic methods provide opportunities to increase testing speed compared with conventional culture-based approaches.

The Gulf region is also developing more sophisticated companion animal and equine veterinary services. High-value horses create specialized diagnostic requirements, while urban pet ownership supports routine Clinical Pathology. Regional growth remains constrained by shortages of trained laboratory personnel and uneven access to advanced equipment. A centralized laboratory capable of returning selected results within approximately 24 hours can serve multiple clinics, making reference testing economically preferable to installing specialized equipment at every veterinary facility. Investment in specimen logistics and digital result delivery will be important for improving regional coverage.

List of Top Veterinary Reference Laboratory (VRL) Companies

• IDEXX Laboratories, Inc.
• VCA, Inc.
• GD Animal Health
• Greencross Ltd.
• Zoetis
• Gribbles Veterinary
• Phoenix Lab
• Neogen Corporation
• ProtaTek International, Inc.

Top 2 Companies Market Share

IDEXX Laboratories, Inc.: IDEXX Laboratories, Inc. is estimated to hold approximately 32% share within the supplied competitive framework, supported by a broad veterinary diagnostics ecosystem spanning reference laboratory services, chemistry, hematology, molecular testing, pathology, software, and in-clinic diagnostic technologies. During May 2026, the company expanded its fecal antigen testing platform with an additional tapeworm detection capability and integrated SDMA into commonly used chemistry profiles. Its strategy increasingly connects routine laboratory testing with advanced biomarkers and digital practice workflows, strengthening recurring diagnostic relationships with veterinary clinics.

Zoetis: Zoetis is estimated to account for approximately 18% share within the analyzed competitive framework, giving the top 2 supplied companies a combined estimated share of approximately 50%. Its diagnostics network expanded materially during 2025 with a new 32,000-square-foot Louisville reference laboratory and the acquisition of a multi-location pathology group in the United Kingdom and Ireland. In July 2026, the company also announced an agreement to acquire a veterinary teleradiology provider offering 24/7 specialist services, advancing its strategy toward an integrated Virtual Reference Laboratory model.

Investment Analysis

Investment in veterinary reference laboratories is increasingly concentrated on centralized high-throughput facilities, molecular equipment, digital pathology, laboratory automation, and logistics. The 32,000-square-foot reference laboratory opened in Louisville during 2025 demonstrates how location can be as important as analytical capacity because proximity to a major international air hub reduces specimen transit and handling. Centralized laboratories can spread the cost of sophisticated equipment across thousands of specimens while individual clinics use external services for tests that are not performed frequently enough to justify dedicated analyzers. Molecular Diagnostics, currently representing approximately 19% of the supplied type structure, is an especially attractive investment area because PCR automation can support companion animal testing and high-volume livestock surveillance.

Digital investment is expanding alongside physical laboratory capacity. AI-enabled hematology now provides as many as 24 parameters at the point of care, creating pressure for reference laboratories to offer deeper interpretation rather than basic numerical results alone. Virtual networks are therefore attracting investment in cloud infrastructure, image management, AI-assisted reporting, specialist workflows, and remote consultation. The July 2026 agreement to acquire a teleradiology provider offering 24/7 access illustrates this transition. Investment opportunities are also emerging in Asia-Pacific, where regional demand is projected to expand approximately 6.8% annually and where laboratory access remains uneven between major metropolitan centers and less-developed areas.

New Product Development

New product development is increasingly focused on faster, more informative, and digitally connected diagnostic workflows. Hematology provides a clear example: a cartridge-based AI-powered platform launched in 2025 was expanded in April 2026 to provide 24 parameters, adding cellular hemoglobin concentration mean and plateletcrit. Reference laboratories are responding by integrating advanced interpretation, pathology, and confirmatory testing with routine analyzer outputs. Clinical Chemistry is also becoming more informative as biomarkers such as SDMA are integrated into commonly ordered chemistry profiles. These developments allow veterinarians to obtain additional clinical information without necessarily increasing the number of separate specimen submissions.

Molecular and antigen-based test development is expanding test menus for infectious and parasitic disease. In May 2026, a major veterinary diagnostic provider added taeniid tapeworm detection to an established fecal antigen testing platform, increasing the breadth of parasite identification available through laboratory testing. PCR panels are also becoming more comprehensive, with some livestock assays testing 3 related pathogens within a single enteric panel. Future product development is likely to combine multiple analytes, AI-assisted interpretation, and digital decision support so that one specimen can generate broader clinical insight. This approach can improve efficiency while helping veterinarians manage the growing complexity of diagnostic information.

Five Recent Developments

• July 2026: Zoetis announced an agreement to acquire VitalRADS, expanding its veterinary diagnostics ecosystem with 24/7 teleradiology, mobile ultrasound, outpatient imaging, cloud image storage, and AI-assisted reporting capabilities designed to support a more comprehensive Virtual Reference Laboratory model.
• May 2026: IDEXX Laboratories, Inc. expanded its Fecal Dx antigen testing platform by adding taeniid tapeworm detection, broadening parasite identification capabilities and providing veterinary practices with another diagnostic target within an established laboratory testing workflow.
• April 2026: Zoetis expanded its AI-powered Vetscan OptiCell hematology platform to 24 parameters by adding cellular hemoglobin concentration mean and plateletcrit, bringing additional reference laboratory-level hematology information into point-of-care veterinary workflows.
• November 2025: Zoetis acquired Veterinary Pathology Group, a veterinary diagnostic laboratory organization operating multiple locations across the United Kingdom and Ireland, strengthening its regional pathology capabilities and expanding its reference laboratory footprint beyond its established U.S. diagnostics network.
• May 2025: Zoetis opened a 32,000-square-foot reference laboratory in Louisville, Kentucky, designed to support chemistry, hematology, cytology, microbiology, histology, and additional services while using proximity to a major air-logistics hub to accelerate specimen movement.

Report Coverage

The Veterinary Reference Laboratory (VRL) Market report evaluates industry conditions across the 2026-2035 forecast period using 2025 as the principal market benchmark. Coverage includes the supplied product types Clinical Chemistry, Hematology, Immunodiagnostics, Molecular Diagnostics, and Others, together with the applications Clinical Pathology, Toxicology, Productivity Testing, and Others. Clinical Chemistry is estimated to represent approximately 31% of diagnostic demand, Hematology 22%, Immunodiagnostics 20%, Molecular Diagnostics 19%, and Others 8%. Application analysis places Clinical Pathology at approximately 61%, Toxicology at 15%, Productivity Testing at 13%, and Others at 11%. Regional assessment covers North America at approximately 43%, Europe at 27%, Asia-Pacific at 23%, Middle East & Africa at 4%, and Latin America at approximately 3%.

The competitive assessment covers IDEXX Laboratories, Inc., VCA, Inc., GD Animal Health, Greencross Ltd., Zoetis, Gribbles Veterinary, Phoenix Lab, Neogen Corporation, and ProtaTek International, Inc. Current technology analysis considers AI-enabled hematology platforms providing 24 parameters, centralized reference facilities reaching approximately 32,000 square feet, commercial veterinary tests targeting turnaround within 24 hours, virtual laboratory services providing 24/7 specialist access, and molecular platforms supporting PCR and ELISA testing across multiple animal species. Coverage further evaluates laboratory consolidation, companion animal diagnostics, livestock surveillance, Clinical Pathology, Toxicology, Productivity Testing, digital pathology, specimen logistics, artificial intelligence, laboratory accreditation, investment activity, new diagnostic development, and regional expansion opportunities through 2035.